Welcome to our dedicated page for RedHill Biopharma Ltd. SEC filings (Ticker: RDHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RedHill Biopharma Ltd. files foreign-issuer reports that document its specialty biopharmaceutical business, ADS capital structure and corporate governance. Recent Form 6-K reports incorporate press releases and meeting materials covering Talicia commercialization, RHB-204, RHB-102 and opaganib development disclosures, and clinical or regulatory updates tied to gastrointestinal, infectious-disease and oncology programs.
The company’s SEC record also includes shareholder-meeting notices and voting results for restricted share unit grants and authorized share-capital changes, as well as Nasdaq listing-compliance communications for its American depositary shares. Incorporation-by-reference language links these current reports to Form S-8 equity compensation registrations and Form F-3 shelf registration statements, reflecting recurring disclosure topics around financing capacity, equity plans, governance and material events.
RedHill Biopharma Ltd. filed a Form 6-K to report that it has increased the maximum aggregate offering amount of American Depositary Shares that may be issued and sold under its existing at-the-market equity program with H.C. Wainwright & Co., LLC.
Each American Depositary Share represents ten thousand of RedHill’s ordinary shares. The filing also attaches updated legal opinions and consents as exhibits and incorporates this report by reference into multiple existing Form S-8 and Form F-3 registration statements.
RedHill Biopharma Ltd. amends its Form F-3 prospectus supplement to increase the amount of American Depositary Shares available under its At The Market sales agreement by up to $2,128,000. The supplement states this amount is in addition to $49,690 of ADSs previously sold under the same agreement.
The supplement cites General Instruction I.B.5 of Form F-3 and reports the aggregate market value of Ordinary Shares held by non-affiliates as $6,534,464 based on 59,949,221,000 Ordinary Shares held by non-affiliates (represented by 5,994,922 ADSs and a per-ADS price of $1.09 as of April 30, 2026. The ADSs trade on Nasdaq under the symbol RDHL; the last reported sale price on June 26, 2026 was $0.8786 per ADS.
RedHill Biopharma Ltd. has called its Annual General Meeting of Shareholders for July 28, 2026, at 3:00 p.m. Israel time in Tel Aviv. Holders of ADSs as of June 23, 2026 are entitled to vote.
Shareholders will vote on re-appointing Kesselman & Kesselman (PwC Israel) as auditors for 2026, re-electing Rick D. Scruggs and Dr. Shmuel Cabilly as directors for three-year terms, and approving the continued engagement of co-founder Dror Ben‑Asher as both Chairman of the Board and Chief Executive Officer for another three-year period starting July 28, 2026.
The company had 60,809,201,000 Ordinary Shares outstanding, represented by 6,080,920 ADSs, as of the record date. A quorum requires at least 25% of voting power, and Proposal 3 also needs a special majority of non-controlling, disinterested shareholders. The Board unanimously recommends voting FOR all proposals.
RedHill Biopharma Ltd. closed a previously announced private placement for $6 million in upfront gross proceeds through the sale of 8,571,429 American Depositary Shares (ADSs) and accompanying warrants. The deal also includes series A-1 and A-2 warrants that, if fully exercised for cash, could provide up to approximately $13.4 million in additional gross proceeds.
The company states that the upfront funding is expected to strengthen near-term liquidity and help support a potential acquisition of commercial-stage, revenue-generating pharmaceutical product assets, although no definitive agreement has been signed and completion is uncertain. H.C. Wainwright & Co. acted as exclusive placement agent, and RedHill agreed to file a resale registration statement for the securities issued.
RedHill Biopharma Ltd. entered into a private placement with an accredited investor to sell 8,571,429 American Depositary Shares (or pre-funded warrants) together with Series A-1 and Series A-2 warrants, at a combined purchase price of $0.70 per ADS and accompanying warrants.
The Series A-1 warrants cover up to 8,571,429 ADSs at an exercise price of $0.86 per ADS and are exercisable immediately for five years after the registration statement becomes effective. The Series A-2 warrants cover up to 8,571,429 ADSs at an exercise price of $0.70 per ADS and are exercisable immediately for 18 months after effectiveness.
The company expects gross proceeds of approximately $6 million before fees and expenses, with potential additional gross proceeds of about $13.4 million if all Series A-1 and Series A-2 warrants are exercised for cash. RedHill also issued the placement agent warrants to acquire up to 514,286 ADSs at $0.875 per ADS.
RedHill Biopharma Ltd. filed a Form 6-K to notify holders of its Annual General Meeting of Shareholders scheduled for July 28, 2026. The meeting will be held at the company’s offices in Tel-Aviv at 3:00 p.m. Israel time.
Shareholders and ADS holders of record at the close of business on June 23, 2026 are entitled to receive notice and vote. Attendees will also be able to review and ask questions regarding the company’s financial statements for the year ended December 31, 2025.
The board of directors recommends voting in favor of the proposals described in the proxy materials, and shareholders may submit written position statements by July 17, 2026 under Israel Companies Law procedures.
RedHill Biopharma Ltd. entered a definitive agreement for a private placement of 8,571,429 American Depositary Shares (ADSs) (or equivalents) with accompanying warrants, raising approximately $6 million in gross proceeds at a combined price of $0.70 per ADS and warrants.
Investors receive Series A-1 warrants to purchase up to 8,571,429 ADSs at $0.86 per ADS, exercisable immediately for five years after the resale registration statement becomes effective, and Series A-2 warrants to purchase up to 8,571,429 ADSs at $0.70 per ADS, exercisable immediately for 18 months after effectiveness. If all warrants are exercised for cash, RedHill could receive an additional approximately $13.4 million, bringing potential gross proceeds up to about $19.4 million. The company plans to use part of the net proceeds to support a potential strategic product acquisition and the remainder for working capital, research and development, and general corporate purposes. The securities are being sold in a private placement exempt from SEC registration, with a commitment to file a resale registration statement for the issued securities and underlying ADSs.
RedHill Biopharma reports that the FDA has granted rare pediatric disease designation to its investigational drug opaganib for treating neuroblastoma, a cancer that mainly affects babies and young children. This comes on top of opaganib’s existing orphan drug designation for neuroblastoma.
The new status can make opaganib eligible for a Priority Review Voucher, as well as potential benefits such as faster review, PDUFA fee waivers, tax credits and up to seven years of U.S. market exclusivity if the drug is approved. Preclinical data presented at AACR 2026 showed positive effects of opaganib as an add-on therapy in models of high‑risk neuroblastoma and triple‑negative breast cancer.
Opaganib is a novel, oral sphingosine kinase‑2 selective inhibitor being developed for multiple oncology, viral, inflammatory, metabolic and obesity‑related indications, alongside RedHill’s broader late‑stage pipeline and its commercial gastrointestinal drug Talicia.
RedHill Biopharma reports that it has launched recognition and enforcement proceedings in Korea to collect on a New York Supreme Court final judgment against Kukbo Co. Ltd totaling approximately $10.9 million. The judgment combines a main award of about $8.9 million and roughly $1.95 million for legal fees and expenses, each including accrued 9% statutory interest, which continues to build. The court’s principal award became final in November 2025, and the fee award became final after Kukbo failed to perfect its appeal by the March 2026 deadline, leaving no further appeals available. RedHill has previously obtained a Korean court attachment to help prevent Kukbo from disposing of assets, but it cautions there is no assurance on the timing or amount of any eventual recovery.
RedHill Biopharma reports it is actively discussing potential collaborations to advance its investigational oral drug opaganib for Ebola virus disease, including with the World Health Organization’s SOLIDARITY CORE clinical trial platform and other pharma partners. Opaganib is a host-directed, small molecule SPHK2 inhibitor with antiviral and anti-inflammatory properties in advanced clinical development.
The company highlights preclinical data suggesting filovirus-class activity and a dual mechanism that may block key viral entry pathways and modulate immune dysfunction. In a Phase 3 severe COVID-19 trial, opaganib add-on therapy showed a 70.2% mortality reduction in a remdesivir plus corticosteroids subgroup. RedHill notes more than 470 participants have been exposed to opaganib across studies and expanded access, and that the drug has FDA Orphan Drug designation for neuroblastoma and cholangiocarcinoma and is being studied in an 80-patient Phase 2 prostate cancer trial.
The company emphasizes that opaganib remains an investigational drug, has not been approved by any regulatory authority, and that inclusion in WHO or other Ebola programs is not guaranteed. Extensive forward-looking statement language underlines significant clinical, regulatory, funding and commercial risks across RedHill’s pipeline.